tiprankstipranks
Trending News
More News >

EQL Pharma Expands Memprex© Distribution to BeNeLux with Goodlife Partnership

Story Highlights
  • EQL Pharma AB partners with Goodlife to distribute Memprex© in BeNeLux.
  • Memprex© offers a non-antibiotic treatment for urinary infections, expanding EQL’s market reach.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
EQL Pharma Expands Memprex© Distribution to BeNeLux with Goodlife Partnership

Don’t Miss TipRanks’ Half-Year Sale

EQL Pharma AB ( (SE:EQL) ) just unveiled an update.

EQL Pharma AB has signed a licensing agreement with Goodlife Specialty BV to distribute its key product, Memprex©, in the BeNeLux region, which includes Belgium, the Netherlands, and Luxembourg. Memprex©, a prophylactic treatment for recurring urinary tract infections, offers a non-antibiotic alternative that reduces the risk of developing antibiotic-resistant bacteria. This agreement marks a significant expansion for EQL Pharma into a new market of approximately 30.5 million people, potentially increasing its market presence and revenue streams.

More about EQL Pharma AB

EQL Pharma AB specializes in developing and selling generic drugs that are medically equivalent to original drugs, focusing on niche generics with limited competition. The company operates mainly in the Nordic and European markets, emphasizing prescription drugs and hospital products. EQL Pharma AB is based in Lund and is listed on the Nasdaq Stockholm stock market.

Average Trading Volume: 16,923

Current Market Cap: SEK2.67B

For a thorough assessment of EQL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1